Clinical

Dataset Information

0

Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2


ABSTRACT: In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or no longer amenable to established therapies.

DISEASE(S): Melanoma,Colorectal Neoplasms,Pancreatic Cancer,Pancreatic Neoplasms,Neoplasms

PROVIDER: 2067971 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2012-02-20 | GSE27050 | GEO
2012-02-20 | E-GEOD-27050 | biostudies-arrayexpress
2014-08-20 | E-ERAD-190 | biostudies-arrayexpress
2008-06-11 | E-GEOD-2015 | biostudies-arrayexpress
2008-06-15 | E-GEOD-6676 | biostudies-arrayexpress
2014-02-08 | GSE54797 | GEO
| S-EPMC4530203 | biostudies-other
2023-08-08 | GSE236032 | GEO
2005-12-01 | GSE2015 | GEO
2022-06-28 | PXD031801 | Pride